| Distribution of Each Cell Cycle Phase (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| subG1 | G1 | S | G2 + M | ||||||||||
| Control | 8.1 | ± | 1.4 | 67.6 | ± | 1.2 | 14.2 | ± | 0.6 | 11.3 | ± | 2.1 | |
| Cisplatin | 10 µM | 11.8 | ± | 0.8 | 69.6 | ± | 1.0 | 12.9 | ± | 0.5 | 7.0 | ± | 0.2 |
| 30 µM | 13.3 | ± | 0.6 | 69.7 | ± | 0.3 | 11.9 | ± | 0.6 | 6.3 | ± | 0.4 | |
| 100 µM | 18.3 | ± | 0.3 | 59.7 | ± | 0.7 | 12.3 | ± | 0.5 | 11.0 | ± | 0.5 | |
| Paclitaxel | 0.1 µM | 7.1 | ± | 0.5 | 67.4 | ± | 0.6 | 9.1 | ± | 0.3 | 17.3 | ± | 0.9 |
| 0.3 µM | 7.8 | ± | 0.4 | 66.0 | ± | 0.6 | 11.4 | ± | 2.2 | 15.8 | ± | 2.2 | |
| 1 µM | 8.6 | ± | 0.3 | 66.3 | ± | 0.9 | 9.2 | ± | 0.7 | 16.7 | ± | 0.7 | |
| Aβ1–42 | 36 nM | 8.6 | ± | 0.4 | 68.5 | ± | 1.1 | 8.9 | ± | 0.7 | 14.8 | ± | 0.9 |
| 100 nM | 6.6 | ± | 0.4 | 68.6 | ± | 1.0 | 9.0 | ± | 0.4 | 16.6 | ± | 0.9 | |
| 360 nM | 8.6 | ± | 0.3 | 68.4 | ± | 0.3 | 8.3 | ± | 0.0 | 15.4 | ± | 0.3 | |
| Aβ25–35 | 143 nM | 8.7 | ± | 1.4 | 67.3 | ± | 1.3 | 9.3 | ± | 0.4 | 15.7 | ± | 0.7 |
| 429 nM | 6.6 | ± | 1.2 | 67.4 | ± | 0.8 | 9.8 | ± | 0.6 | 16.9 | ± | 0.8 | |
| 1430 nM | 7.5 | ± | 1.0 | 67.7 | ± | 0.6 | 9.3 | ± | 0.5 | 16.4 | ± | 0.5 | |
| Actinomycin D | 1 µM | 3.3 | ± | 0.2 | 66.4 | ± | 1.2 | 11.4 | ± | 0.4 | 20.8 | ± | 0.4 |
| 2 µM | 3.6 | ± | 1.3 | 66.0 | ± | 1.3 | 15.5 | ± | 1.4 | 16.3 | ± | 1.3 | |